Journal article
Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
J Litt, R Booy, D Bourke, DE Dwyer, A Leeb, P McCloud, AN Stein, M Woodward, AL Cunningham
Human Vaccines and Immunotherapeutics | TAYLOR & FRANCIS INC | Published : 2020
Abstract
Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults aged 70 years, with a 5-year catch-up program (until October 2021) for adults aged 71–79 years. Patterns and impact of the program were evaluated by analysis of vaccine distribution and delivery data and specific antiviral prescription data from the Pharmaceutical Benefits Scheme. During the first 2 years, uptake of funded live attenuated shingles vaccine ZOSTAVAX® (Zoster Virus Vaccine Live; ZVL) was high across the ongoing and catch-up pro..
View full abstractGrants
Funding Acknowledgements
The analyses reported in this manuscript were sponsored by Seqirus (Australia) Pty Ltd. Medical writing assistance was provided by Justine Southby, PhD, CMPP, and Serina Stretton, PhD, CMPP, of ProScribe Envision Pharma Group, and was funded by Seqirus (Australia) Pty Ltd. ProScribe's services complied with international guidelines for Good Publication Practice (GPP3).